LRRK2 Promotes Tau Accumulation, Aggregation and Release

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Molecular Neurobiology

• Publication date

  2015-05-27

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s12035-015-9209-zPMID 26014385
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Differential protein–protein interactions of LRRK1 and LRRK2 indicate roles in distinct cellular signaling pathways

  2014cited by this paper
• PICALM modulates autophagy activity and tau accumulation

  2014cited by this paper
• Leucine‐rich repeat kinase 2 regulates tau phosphorylation through direct activation of glycogen synthase kinase‐3β

  2014cited by this paper
• Regulation of Autophagy by LRRK2 in Caenorhabditis elegans

  2013cited by this paper
• Pathogenic Parkinson’s disease mutations across the functional domains of LRRK2 alter the autophagic/lysosomal response to starvation☆

  2013cited by this paper
• A Direct Interaction between Leucine-rich Repeat Kinase 2 and Specific β-Tubulin Isoforms Regulates Tubulin Acetylation*

  2013cited by this paper
• Juvenile Frontotemporal Dementia with Parkinsonism Associated with Tau Mutation G389R

  2013cited by this paper
• LRRK2 phosphorylates novel tau epitopes and promotes tauopathy

  2013cited by this paper
• LRRK2 secretion in exosomes is regulated by 14-3-3.

  2013cited by this paper
• Tau Clearance Mechanisms and Their Possible Role in the Pathogenesis of Alzheimer Disease

  2013cited by this paper
• Phosphorylation of human Tau protein by microtubule affinity-regulating kinase 2.

  2013cited by this paper
• Tau degradation: the ubiquitin-proteasome system versus the autophagy-lysosome system.

  2013cited by this paper
• Role of LRRK2 kinase activity in the pathogenesis of Parkinson's disease.

  2012cited by this paper
• High LRRK2 Levels Fail to Induce or Exacerbate Neuronal Alpha-Synucleinopathy in Mouse Brain

  2012cited by this paper
• LRRK2 interactions with α-synuclein in Parkinson’s disease brains and in cell models

  2012cited by this paper
• LRRK2 Phosphorylates Tubulin-Associated Tau but Not the Free Molecule: LRRK2-Mediated Regulation of the Tau-Tubulin Association and Neurite Outgrowth

  2012cited by this paper
• Degradation of tau protein by autophagy and proteasomal pathways.

  2012cited by this paper
• Autophagic degradation of tau in primary neurons and its enhancement by trehalose.

  2012cited by this paper
• Proteostasis of tau. Tau overexpression results in its secretion via membrane vesicles

  2012cited by this paper
• Trans-cellular Propagation of Tau Aggregation by Fibrillar Species*

  2012cited by this paper
• Presynaptic dysfunction in Parkinson's disease: a focus on LRRK2.

  2012cited by this paper
• Tau Overexpression Results in Its Secretion via Membrane Vesicles

  2012cited by this paper
• The Parkinson's disease protein LRRK2 impairs proteasome substrate clearance without affecting proteasome catalytic activity

  2011cited by this paper
• α-Synuclein aggregation and transmission are enhanced by leucine-rich repeat kinase 2 in human neuroblastoma SH-SY5Y cells.

  2011cited by this paper
• Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study.

  2011cited by this paper
• The role of tau kinases in Alzheimer's disease.

  2010cited by this paper
• Mechanisms in dominant parkinsonism: The toxic triangle of LRRK2, α‐synuclein, and tau

  2010cited by this paper
• Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice.

  2010cited by this paper
• Zooming into protein oligomerization in neurodegeneration using BiFC.

  2010cited by this paper
• 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization

  2010cited by this paper
• The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease

  2010cited by this paper
• Leucine‐rich repeat kinase 2 phosphorylates brain tubulin‐beta isoforms and modulates microtubule stability – a point of convergence in Parkinsonian neurodegeneration?

  2009cited by this paper
• Phosphorylation of Ezrin/Radixin/Moesin Proteins by LRRK2 Promotes the Rearrangement of Actin Cytoskeleton in Neuronal Morphogenesis

  2009cited by this paper
• Concentration-dependent effects of proteasomal inhibition on tau processing in a cellular model of tauopathy.

  2009cited by this paper
• Leucine-Rich Repeat Kinase 2 interacts with Parkin, DJ-1 and PINK-1 in a Drosophila melanogaster model of Parkinson's disease.

  2009cited by this paper
• The tau of MARK: a polarized view of the cytoskeleton.

  2009cited by this paper
• Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.

  2009cited by this paper
• Role of autophagy in G2019S‐LRRK2‐associated neurite shortening in differentiated SH‐SY5Y cells

  2008cited by this paper
• The Roc domain of leucine‐rich repeat kinase 2 is sufficient for interaction with microtubules

  2008cited by this paper
• Kinase activity of mutant LRRK2 mediates neuronal toxicity

  2006cited by this paper
• Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase

  2006cited by this paper
• Kinase activity is required for the toxic effects of mutant LRRK2/dardarin.

  2006cited by this paper
• Monitoring activity and inhibition of 26S proteasomes with fluorogenic peptide substrates.

  2005cited by this paper
• Application and analysis of the GFPu family of ubiquitin-proteasome system reporters.

  2005cited by this paper
• Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity.

  2005cited by this paper
• Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease.

  2004cited by this paper
• Inefficient degradation of truncated polyglutamine proteins by the proteasome

  2004cited by this paper
• Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology.

  2004cited by this paper
• Initiation and Synergistic Fibrillization of Tau and Alpha-Synuclein

  2003cited by this paper
• Proteasome inhibition by paired helical filament‐tau in brains of patients with Alzheimer's disease

  2003cited by this paper
• Proteasomal degradation of tau protein

  2002cited by this paper
• Hyperphosphorylation induces self-assembly of τ into tangles of paired helical filaments/straight filaments

  2001cited by this paper
• Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease.

  1989cited by this paper

• Longitudinal decline in striatal DAT binding in LRRK2 Parkinson’s disease: connections with CSF α-synuclein seeding activity

  2025cites this paper
• LRRK2 Kinase Inhibitor PF-06447475 Protects Drosophila melanogaster against Paraquat-Induced Locomotor Impairment, Life Span Reduction, and Oxidative Stress

  2024cites this paper
• The LRRK2 kinase substrates RAB8a and RAB10 contribute complementary but distinct disease-relevant phenotypes in human neurons

  2024cites this paper
• The LRRK2 kinase substrates Rab8a and Rab10 contribute complementary but distinct disease-relevant phenotypes in human neurons

  2023cites this paper
• Mixed pathology as a rule, not exception: Time to reconsider disease nosology.

  2023cites this paper
• Small-molecule LRRK2 inhibitors for PD therapy: Current achievements and future perspectives.

  2023cites this paper
• Prediction of Alzheimer’s Disease Using Patterns of Methylation Levels in Key Immunologic-Related Genes

  2022cites this paper
• Pathophysiological evaluation of the LRRK2 G2385R risk variant for Parkinson’s disease

  2022cites this paper
• Kinases on Double Duty: A Review of UniProtKB Annotated Bifunctionality within the Kinome

  2022cites this paper
• Molecular Pathways Involved in LRRK2-Linked Parkinson’s Disease: A Systematic Review

  2022influential citation
• Modelling the Functional Genomics of Parkinson’s in Caenorhabditis elegans: LRRK2 and Beyond

  2021cites this paper
• Potential role of cannabidiol in Parkinson’s disease by targeting the WNT/β-catenin pathway, oxidative stress and inflammation

  2021cites this paper
• Modelling the functional genomics of Parkinson’s disease in Caenorhabditis elegans: LRRK2 and beyond

  2021cites this paper
• Parkinson’s Disease: Potential Actions of Lithium by Targeting the WNT/β-Catenin Pathway, Oxidative Stress, Inflammation and Glutamatergic Pathway

  2021cites this paper
• 18F-Labelled pyrrolopyrimidines reveal brain leucine-rich repeat kinase 2 expression implicated in Parkinson's disease.

  2021cites this paper
• Circadian rhythms, Neuroinflammation and Oxidative Stress in the Story of Parkinson’s Disease

  2020cites this paper
• Genetic determinants of survival in progressive supranuclear palsy: a genome-wide association study.

  2020cites this paper
• Knockin’ on heaven’s door: Molecular mechanisms of neuronal tau uptake

  2020cites this paper
• Tau accumulates in Crohn’s disease gut

  2020cites this paper
• Common variation at the LRRK2 locus is associated with survival in the primary tauopathy progressive supranuclear palsy

  2020cites this paper
• LRRK2 Biology from structure to dysfunction: research progresses, but the themes remain the same

  2019cites this paper
• Induced pluripotent stem cell‐based modeling of mutant LRRK2‐associated Parkinson's disease

  2019cites this paper
• Modeling G2019S-LRRK2 Sporadic Parkinson's Disease in 3D Midbrain Organoids

  2019cites this paper
• LRRK2, alpha-synuclein, and tau: partners in crime or unfortunate bystanders?

  2019cites this paper
• Rab GTPases as Physiological Substrates of LRRK2 Kinase

  2019cites this paper
• What Have We Learned from Cerebrospinal Fluid Studies about Biomarkers for Detecting LRRK2 Parkinson’s Disease Patients and Healthy Subjects with Parkinson’s-Associated LRRK2 Mutations?

  2019cites this paper
• LRRK2 G2019S kinase activity triggers neurotoxic NSF aggregation

  2019cites this paper
• Genetic mimics of the non-genetic atypical parkinsonian disorders - the 'atypical' atypical.

  2019cites this paper
• Characterization of the activity, aggregation, and toxicity of heterodimers of WT and ALS-associated mutant Sod1

  2019cites this paper
• Update on the association between alpha‐synuclein and tau with mitochondrial dysfunction: Implications for Parkinson's disease

  2019cites this paper
• Mitochondrial function and autophagy: integrating proteotoxic, redox, and metabolic stress in Parkinson's disease

  2018cites this paper
• Designing antibodies against LRRK2-targeted tau epitopes

  2018cites this paper
• The role of LRRK2 in cell signalling.

  2018cites this paper
• The role of LRRK2 in cytoskeletal dynamics.

  2018cites this paper
• Tau Protein Squired by Molecular Chaperones During Alzheimer’s Disease

  2018cites this paper
• Oxidative stress and neuroinflammation in the story of Parkinson’s disease: Could targeting these pathways write a good ending?

  2018cites this paper
• G2019S LRRK2 enhances the neuronal transmission of tau in the mouse brain

  2018cites this paper
• Other Proteins Involved in Parkinson's Disease and Related Disorders.

  2017influential citation
• Targeting LRRK2 in Parkinson’s disease: an update on recent developments

  2017cites this paper
• LRRK2 at the Crossroad Between Autophagy and Microtubule Trafficking

  2017cites this paper
• EFhd2, a Protein Linked to Alzheimer's Disease and Other Neurological Disorders

  2016cites this paper
• Pathogenic LRRK2 mutations, through increased kinase activity, produce enlarged lysosomes with reduced degradative capacity and increase ATP13A2 expression.

  2015cites this paper
• The associations between Parkinson’s disease and cancer: the plot thickens

  2015cites this paper